Trial Profile
A PILOT STUDY OF A POLYVALENT VACCINE-KLH CONJUGATE + OPT-821 GIVEN IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN SECOND OR GREATER COMPLETE OR PARTIAL CLINICAL REMISSION.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; OPT 821; Polyvalent antigen-KLH conjugate vaccine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Registrational
- 01 Jan 2023 Results reporting long-term outcomes at follow-up continued until Mar 2021 published in the Cancer Immunology Immunotherapy
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.
- 15 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.